Myelodysplastic Syndrome: Our Clinical Trials

Your Memorial Sloan Kettering physician can help you decide whether treatment through a clinical trial is right for you. Sometime clinical trials should be considered as the first treatment for myelodysplastic syndromes (MDS). If you have already received standard treatments, then clinical trials may be an option to consider in addition to supportive care.

Here you can find a continually updated listing of Memorial Sloan Kettering's current clinical trials for adults with MDS. To learn more about a study, choose from the list below.

Showing 18 trials
Title Investigatorsort icon
A Phase II Study of 5'-Azacitidine to Prevent Recurrence in Patients Who Had a Donated Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndromes
[Protocol 13-192]
Tamari, Roni, MD
A Phase I Study of EPZ-5676 in Patients with Relapsed/Refractory Leukemia and Other Advanced Hematologic Cancers
[Protocol 12-181]
Tallman, Martin, MD
A Phase I Study of AG-221 in Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndromes with an IDH2 Mutation
[Protocol 13-154]
Stein, Eytan, MD
A Phase I Study of CPI-0610 in Patients with Acute Leukemia, Myelodysplastic Syndromes, or Myelodysplastic/Myeloproliferative Neoplasms
[Protocol 14-136]
Stein, Eytan, MD
A Study of Allogeneic Stem Cell Transplantation in HIV-Infected Patients with Hematologic Cancers
[Protocol 12-092]
Sauter, Craig, MD
A Phase I/II Study Assessing BPX-501 T Cells Given After Partially Mismatched Related T Cell-Depleted Stem Cell Transplantation in Patients with Hematologic Cancers
[Protocol 13-181]
Perales, Miguel-Angel, MD
A Study of Posaconazole Versus Micafungin to Protect Against Invasive Fungal Infections in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome
[Protocol 10-038]
Papanicolaou, Genovefa, MD
A Phase I/II Study of Oral Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes after Receiving a Stem Cell Transplant from a Donor
[Protocol 13-160]
Papadopoulos, Esperanza, MD
A Phase I Study of WT1-Sensitized T cells for Residual or Relapsed Leukemia after Allogeneic Hematopoietic Progenitor Cell Transplantation
[Protocol 07-055]
O'Reilly, Richard, MD
A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
[Protocol 10-050]
O'Reilly, Richard, MD
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLA-Compatible Donor
[Protocol 12-053]
O'Reilly, Richard, MD
A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Relapsed/Refractory
[Protocol 13-220]
Moskowitz, Craig, MD
A Phase I Study of HDM201 in Patients with Advanced Cancers and a Normal TP53 Gene
[Protocol 14-139]
Hyman, David, MD
A Phase II Study of Palifermin with or without Leuprolide After T-Cell-Depleted Allogeneic Stem Cell Transplantation
[Protocol 12-077]
Goldberg, Jenna, MD
A Phase II Study of Bulk Versus Fractionated Stem Cell Infusions in Patients with Hematologic Cancers Undergoing Stem Cell Transplantation
[Protocol 12-016]
Giralt, Sergio, MD
A Study Comparing Reduced-Intensity Allogeneic Stem Cell Transplantation with Best Supportive Therapy in Older Patients with Myelodysplastic Syndromes
[Protocol 14-123]
Castro-Malaspina, Hugo, MD
A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Acute Leukemia or Myelodysplasia
[Protocol 08-087]
Barker, Juliet, MBBS
Transplantation of Unrelated Donor Double-Unit Cord Blood with T-Cell-Depleted Stem Cells for Patients with High-Risk Hematologic Cancers
Relapsed/Refractory
[Protocol 12-153]
Barker, Juliet, MBBS